Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136072 | 0.82 | LMNA (0.59) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL952111 | 0.82 | POLB (0.58) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL141535 | 0.81 | ALDH1A1 (0.51) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL13405755 | 0.80 | MAPT (0.61) | MAPTALDH1A1MAPK1POLBTDP1 | |
| Bromide SCHEMBL3542156 | 0.79 | MAPT (0.60) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL9689496 | 0.79 | MAPT (0.46) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL14377339 | 0.78 | ALDH1A1 (0.51) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL3715234 | 0.76 | GRM5 (0.46) | MAPTALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL9014675 | 0.76 | ADRB1 (0.49) | ALDH1A1RECQLADRB1CYP1A2 | |
| SCHEMBL513428 | 0.75 | GRM5 (0.60) | MAPTALDH1A1MAPK1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864261-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2005-03-08 | — | — | US | disclosed |
| US-20040053914-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053914-A1 | Therapeutic agents useful for treating pain | SMN1; SMN2, OPRM1, PSEN1 | MAPT 5/4885ALDH1A1 416/4885MAPK1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.